NetworkNewsBreaks – Processa Pharmaceuticals Inc
Post# of 40
(Total Views: 303)
Posted On: 11/13/2020 3:34:52 PM
NetworkNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Announces Q3 2020 Results, Provides Corporate Update
Processa Pharmaceuticals (NASDAQ: PCSA), a clinical-stage biopharmaceutical company focused on the development of drug products intended to provide treatment for and improve the survival and/or quality of life for patients with unmet medical needs or no alternative treatment, on Thursday released its financial results for the third quarter of 2020. In addition, Processa provided a business update via conference call, for which the replay may be accessed at https://nnw.fm/D1KVg or by dialing 877-481-4010 (Toll-free) or 919-882-2331 (International) and entering replay passcode: 38528. “The third quarter was a period of tremendous value creation. Over that time, we in-licensed important clinical drug candidates PCS12852 and PCS6422, uplisted to Nasdaq and closed a $19.2 million public offering,” Dr. David Young, CEO and chairman of Processa, stated in the press release. “Due to those achievements, we now have sufficient funds to complete three trials for three distinct markets, each exceeding $1 billion. Importantly, we are developing products for which existing clinical evidence of efficacy has already been established. With key milestones to announce over the next 12-18 months, including interim data for PCS6422 in 3Q21 and PCS499 in 4Q21, we are excited about the near-term opportunity of increasing shareholder value.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Processa Pharmaceuticals (NASDAQ: PCSA), a clinical-stage biopharmaceutical company focused on the development of drug products intended to provide treatment for and improve the survival and/or quality of life for patients with unmet medical needs or no alternative treatment, on Thursday released its financial results for the third quarter of 2020. In addition, Processa provided a business update via conference call, for which the replay may be accessed at https://nnw.fm/D1KVg or by dialing 877-481-4010 (Toll-free) or 919-882-2331 (International) and entering replay passcode: 38528. “The third quarter was a period of tremendous value creation. Over that time, we in-licensed important clinical drug candidates PCS12852 and PCS6422, uplisted to Nasdaq and closed a $19.2 million public offering,” Dr. David Young, CEO and chairman of Processa, stated in the press release. “Due to those achievements, we now have sufficient funds to complete three trials for three distinct markets, each exceeding $1 billion. Importantly, we are developing products for which existing clinical evidence of efficacy has already been established. With key milestones to announce over the next 12-18 months, including interim data for PCS6422 in 3Q21 and PCS499 in 4Q21, we are excited about the near-term opportunity of increasing shareholder value.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)